Boehringer Ingelheim International Gmbh

Hartmut Beug

Matthew Cotten

Ernst Wagner

Max L Birnstiel

Karl-Heinz Heider

Birgit Jung

Peter Seither

Andreas Zophel

Renate Konopitzky

Horst Johann Ahorn

Andreas Weith

Norbert Kraut

Peter Steinlein

Martin Oft

Martin Jechlinger

Ernst Reichmann

Ido M Tamir

Oliver Wessely

Eva Deiner

Stefan Gruenert

Maartje Marie Von Lindern

Thomas Waerner

Harald Kandolf

The functional characterization of ILEI to be a novel cytokine involved in epithelial/mesenchymal transition and the identification of biologically active ILEI provides the basis for generating ILEI inhibitors, in particular anti-ILEI antibodies, that are useful in the therapy of cancer, fibrosis and COPD.

Antibodies to interleukin-like epithelial-mesenchymal transition inducer (ILEI)

Genetics units for inhibiting the function of RNA

Pharmaceutical compositions containing as active compound a substance which inhibits the activity of TGF&bgr; on tumour cells of epithelial origin, for the treatment of epithelial, invasive tumour diseases which are characterized by a reversible transition of the cells from an epithelial, non-invasive state into a fibroblastoid, invasive state. The pharmaceutical composition contains a TGF&bgr; inhibitor, preferably combined with an Ras inhibitor. Process for screening substances for the treatment of epithelial, invasive tumour diseases.

Methods of screening for pharmacologically active compounds for the treatment of tumour diseases

Process for preparing and cultivating hematopoietic progenitor cells

The invention relates to a system for transporting nucleic acids into the cell, which is effected by receptor-mediated endocytosis. Using a transferrin-polycation conjugate, a complex can be formed with the polyanionic nucleic acid. This complex is bound to the transferrin receptor, which is highly regulated in growing cells, and absorbed into the cell. Suitable nucleic acids include those which inhibit specific genes or the RNA function, such as antisense oligonucleotides or ribozymes or the genes coding for them. The invention further relates to a process for introducing nucleic acids into the cells, transferrin-polycation/nucleic acid complexes and pharmaceutical preparations containing them.

Protein-polycation nucleic acid complexes and methods of use

The invention relates to a system for transporting nucleic acids into the cell, which is effected by receptor-mediated endocytosis. Using a transferrin-polycation conjugate, a complex can be formed with the polyanionic nucleic acid. This complex is bound to the transfertin receptor, which is highly regulated in growing cells, and absorbed into the cell. Suitable nucleic acids include those which inhibit specific genes or the RNA function, such as antisense oligonucleotides or ribozymes or the genes coding for them. The invention further relates to a process for introducing nucleic acids into the cells, transferrin-polycation/nucleic acid complexes and pharmaceutical preparations containing them.

Protein-polycation conjugates

Growing community of inventors

Vienna, Austria

Hartmut Beug